Literature DB >> 15670890

RAD51, genomic stability, and tumorigenesis.

Christine Richardson1.   

Abstract

Genomic instability is characteristic of malignant cells, and a strong correlation exists between abnormal karyotype and tumorigenicity. Increased expression of the homologous recombination and DNA repair protein Rad51 has been reported in immortalized cell lines and multiple primary tumor cell types which could alter recombination pathways to contribute to the chromosomal rearrangements found in these cells. In addition, Rad51 participates in a complex network of interactions that includes DNA damage sensors, tumor suppressors, and cell cycle and apoptotic regulators, and mutation of many of these proteins have also been associated with tumor initiation or progression. Insights into the connection between disregulated Rad51 and malignant phenotype indicate that Rad51 is a potential target for new anti-cancer regimens including those that use siRNA technology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670890     DOI: 10.1016/j.canlet.2004.08.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  40 in total

1.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Genetic 135G/C polymorphism of RAD51 gene and risk of cancer: a meta-analysis of 28,956 cases and 28,372 controls.

Authors:  Bei-Bei Zhang; Dao-Gang Wang; Chao Xuan; Gui-Li Sun; Kai-Feng Deng
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

3.  DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells.

Authors:  Zhiyong Mao; Ying Jiang; Xiang Liu; Andrei Seluanov; Vera Gorbunova
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

4.  MiRNA-binding site functional polymorphisms in DNA repair genes RAD51, RAD52, and XRCC2 and breast cancer risk in Chinese population.

Authors:  Jingjing Cao; Chenglin Luo; Rui Peng; Qiaoyun Guo; Kaijuan Wang; Peng Wang; Hua Ye; Chunhua Song
Journal:  Tumour Biol       Date:  2016-10-10

5.  RAD51 135G>C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women.

Authors:  Ana M Krivokuca; Emina J Malisic; Jelena D Dobricic; Ksenija V Brotto; Milena R Cavic; Radmila N Jankovic; Zorica I Tomasevic; Mirjana V Brankovic-Magic
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

6.  Ginsenosides synergize with mitomycin C in combating human non-small cell lung cancer by repressing Rad51-mediated DNA repair.

Authors:  Min Zhao; Dan-Dan Wang; Yuan Che; Meng-Qiu Wu; Qing-Ran Li; Chang Shao; Yun Wang; Li-Juan Cao; Guang-Ji Wang; Hai-Ping Hao
Journal:  Acta Pharmacol Sin       Date:  2017-08-24       Impact factor: 6.150

7.  RAD51 variant proteins from human lung and kidney tumors exhibit DNA strand exchange defects.

Authors:  Michelle C Silva; Milagros D Morrical; Katie E Bryan; April M Averill; Julie Dragon; Jeffrey P Bond; Scott W Morrical
Journal:  DNA Repair (Amst)       Date:  2016-04-25

8.  Association between RAD51 gene polymorphism (-135G/C) and susceptibility of myelodysplastic syndrome and acute leukemia: evidence based on a meta-analysis.

Authors:  Ya-zhou He; Xin Hu; Xiao-sa Chi; Yuan-chuan Zhang; Xiang-Bing Deng; Ming-tian Wei; Zi-qiang Wang; Yan-hong Zhou
Journal:  Tumour Biol       Date:  2013-08-17

9.  RAD51 polymorphisms and breast cancer risk.

Authors:  Mojgan Hosseini; Massoud Houshmand; Ahmad Ebrahimi
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

10.  High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.

Authors:  Xiuli Chen; Dong Qian; Jingjing Cheng; Yong Guan; Bin Zhang; Xiaofeng Ding; Jing Zeng; Xi Chen; Puchun Er; Furong Zhang; Na Zhao; Xiaocen Chen; Lujun Zhao; Zhiyong Yuan; Qingsong Pang; Ping Wang
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.